Ross Baker

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3702072/publications.pdf

Version: 2024-02-01

109 papers	8,253 citations	76294 40 h-index	46771 89 g-index
109 all docs	109 docs citations	109 times ranked	8166 citing authors

#	Article	IF	Citations
1	Low-Molecular-Weight Heparin versus a Coumarin for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer. New England Journal of Medicine, 2003, 349, 146-153.	13.9	2,344
2	Randomized Comparison of Low Molecular Weight Heparin and Coumarin Derivatives on the Survival of Patients With Cancer and Venous Thromboembolism. Journal of Clinical Oncology, 2005, 23, 2123-2129.	0.8	439
3	Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients. New England Journal of Medicine, 2016, 375, 534-544.	13.9	379
4	Phase 3 Study of Recombinant Factor IX Fc Fusion Protein in Hemophilia B. New England Journal of Medicine, 2013, 369, 2313-2323.	13.9	307
5	Longâ€term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy. British Journal of Haematology, 2013, 161, 411-423.	1.2	234
6	Association Between High Homocyst(e)ine and Ischemic Stroke due to Large- and Small-Artery Disease but Not Other Etiologic Subtypes of Ischemic Stroke. Stroke, 2000, 31, 1069-1075.	1.0	229
7	PRODIGE: a randomized placeboâ€controlled trial of dalteparin lowâ€molecularâ€weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma. Journal of Thrombosis and Haemostasis, 2010, 8, 1959-1965.	1.9	211
8	Persistent endotheliopathy in the pathogenesis of long COVID syndrome. Journal of Thrombosis and Haemostasis, 2021, 19, 2546-2553.	1.9	208
9	Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness. New England Journal of Medicine, 2018, 379, 1118-1127.	13.9	205
10	Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. Lancet, The, 2021, 397, 2361-2371.	6.3	177
11	Common variants at 6p21.1 are associated with large artery atherosclerotic stroke. Nature Genetics, 2012, 44, 1147-1151.	9.4	152
12	Endothelial and Platelet Activation in Acute Ischemic Stroke and Its Etiological Subtypes. Stroke, 2003, 34, 2132-2137.	1.0	147
13	Inherited Thrombophilia in Ischemic Stroke and Its Pathogenic Subtypes. Stroke, 2001, 32, 1793-1799.	1.0	133
14	Hepatitis C virus drug resistance and immune-driven adaptations: Relevance to new antiviral therapy. Hepatology, 2009, 49, 1069-1082.	3.6	131
15	A Multicenter Trial of Vena Cava Filters in Severely Injured Patients. New England Journal of Medicine, 2019, 381, 328-337.	13.9	117
16	Treatment of Proximal Deep Vein Thrombosis With a Novel Synthetic Compound (SR90107A/ORG31540) With Pure Antiâ€“Factor Xa Activity. Circulation, 2000, 102, 2726-2731.	1.6	109
17	Neutrophil CD11B Expression and Neutrophil Activation in Pre-Eclampsia. Clinical Science, 1997, 92, 37-44.	1.8	97
18	Thrombin generation using the calibrated automated thrombinoscope to assess reversibility of dabigatran and rivaroxaban. Thrombosis and Haemostasis, 2014, 112, 989-995.	1.8	97

#	Article	IF	Citations
19	Platelet glycoprotein IbÎ± Kozak polymorphism is associated with an increased risk of ischemic stroke. Blood, 2001, 98, 36-40.	0.6	94
20	Homocysteine-Lowering Treatment With Folic Acid, Cobalamin, and Pyridoxine Does Not Reduce Blood Markers of Inflammation, Endothelial Dysfunction, or Hypercoagulability in Patients With Previous Transient Ischemic Attack or Stroke. Stroke, 2005, 36, 144-146.	1.0	94
21	New guidelines from the Thrombosis and Haemostasis Society of Australia and New Zealand for the diagnosis and management of venous thromboembolism. Medical Journal of Australia, 2019, 210, 227-235.	0.8	89
22	The platelet Fc receptor, FcÎ³RIIa. Immunological Reviews, 2015, 268, 241-252.	2.8	87
23	Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2021, 22, 678-689.	5.1	83
24	Rapid detection of hereditary and acquired platelet storage pool deficiency by flow cytometry. British Journal of Haematology, 1995, 89, 117-123.	1.2	80
25	Dual ITAM-mediated proteolytic pathways for irreversible inactivation of platelet receptors: de-ITAM-izing FcÎ³RIIa. Blood, 2008, 111, 165-174.	0.6	77
26	Soluble Glycoprotein VI Is Raised in the Plasma of Patients With Acute Ischemic Stroke. Stroke, 2011, 42, 498-500.	1.0	77
27	Incidence and risk factors for fatal pulmonary embolism after major trauma: a nested cohort study. British Journal of Anaesthesia, 2010, 105, 596-602.	1.5	74
28	Protein Z in Ischemic Stroke and its Etiologic Subtypes. Stroke, 2003, 34, 2415-2419.	1.0	73
29	Efficacy and safety of rVIII-SingleChain: results of a phase 1/3 multicenter clinical trial in severe hemophilia A. Blood, 2016, 128, 630-637.	0.6	69
30	Association between phosphodiesterase 4D gene and ischaemic stroke. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 77, 1067-1069.	0.9	65
31	Effects of regular ingestion of black tea on haemostasis and cell adhesion molecules in humans. European Journal of Clinical Nutrition, 2001, 55, 881-886.	1.3	64
32	Current State and Novel Approaches of Antiplatelet Therapy. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 1327-1338.	1.1	62
33	Reducing Errors in Identification of von Willebrand Disease: The Experience of the Royal College of Pathologists of Australasia Quality Assurance Program. Seminars in Thrombosis and Hemostasis, 2006, 32, 505-513.	1.5	60
34	Divergent adaptation of hepatitis C virus genotypes 1 and 3 to human leukocyte antigen-restricted immune pressure. Hepatology, 2009, 50, 1017-1029.	3.6	60
35	ADAMTS13 regulation of VWF multimer distribution in severe COVIDâ€19. Journal of Thrombosis and Haemostasis, 2021, 19, 1914-1921.	1.9	58
36	Compromised ITAMâ€based platelet receptor function in a patient with immune thrombocytopenic purpura. Journal of Thrombosis and Haemostasis, 2008, 6, 1175-1182.	1.9	56

#	Article	IF	Citations
37	Platelet function in myeloproliferative disorders: Characterization and sequential studies show multiple platelet abnormalities, and change with time. European Journal of Haematology, 1988, 40, 267-272.	1.1	55
38	Premature ischaemic heart disease and the gene for coagulation factor V. Nature Medicine, 1995, 1, 185-185.	15.2	52
39	Neutralising rivaroxaban induced interference in laboratory testing for lupus anticoagulant (LA): A comparative study using DOAC Stop and andexanet alfa. Thrombosis Research, 2019, 180, 10-19.	0.8	47
40	Validation of whole blood impedance aggregometry as a new diagnostic tool for HIT. Thrombosis and Haemostasis, 2012, 107, 575-583.	1.8	43
41	Once-Daily Enoxaparin in The Outpatient Setting Versus Unfractionated Heparin in Hospital for the Treatment of Symptomatic Deep-Vein Thrombosis. Journal of Thrombosis and Thrombolysis, 2005, 19, 173-181.	1.0	41
42	Comparison of Fatal or Irreversible Events With Extendedâ€Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy. Journal of the American Heart Association, 2017, 6, .	1.6	40
43	C-reactive protein in ischemic stroke and its etiologic subtypes. Journal of Stroke and Cerebrovascular Diseases, 2003, 12, 74-81.	0.7	38
44	VITATOPS, the VITAmins TO Prevent Stroke Trial: Rationale and Design of a Randomised Trial of B-Vitamin Therapy in Patients with Recent Transient Ischaemic Attack or Stroke (NCT00097669) (ISRCTN74743444). International Journal of Stroke, 2007, 2, 144-150.	2.9	38
45	Clinical efficacy and safety of the factor VIII/von Willebrand factor concentrate BIOSTATE^{Â®} in patients with von Willebrandâ€™s disease: a prospective multiâ€centre study. Haemophilia, 2010, 16, 615-624.	1.0	37
46	Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. Thrombosis and Haemostasis, 2007, 97, 922-930.	1.8	36
47	Desmopressin therapy to assist the functional identification and characterisation of von Willebrand disease: Differential utility from combining two (VWF:CB and VWF:RCo) von Willebrand factor activity assays?. Thrombosis Research, 2009, 123, 862-868.	0.8	36
48	Clinical care of pregnant and postpartum women with COVIDâ€19: Living recommendations from the National COVIDâ€19 Clinical Evidence Taskforce. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2020, 60, 840-851.	0.4	36
49	Collagen platelet receptor polymorphisms integrin alpha2beta1 C807T and GPVI Q317L and risk of ischemic stroke. Journal of Thrombosis and Haemostasis, 2003, 1, 963-970.	1.9	35
50	Switching to recombinant factor <scp>IX</scp> Fc fusion protein prophylaxis results in fewer infusions, decreased factor <scp>IX</scp> consumption and lower bleeding rates. British Journal of Haematology, 2015, 168, 113-123.	1.2	31
51	Long-term safety and efficacy of extended-interval prophylaxis with recombinant factor IX Fc fusion protein (rFIXFc) in subjects with haemophilia B. Thrombosis and Haemostasis, 2017, 117, 508-518.	1.8	31
52	Efficacy and safety of a high purity, double virus inactivated factor VIII/von Willebrand factor concentrate (Biostateï¿½) in patients with von Willebrand disorder requiring invasive or surgical procedures. Haemophilia, 2007, 13, 144-148.	1.0	27
53	Micro-Ribonucleic AcidÂ494 regulation of proteinÂS expression. Journal of Thrombosis and Haemostasis, 2013, 11, 1547-1555.	1.9	27
54	Construction of a Bivalent Thrombin Binding Aptamer and Its Antidote with Improved Properties. Molecules, 2017, 22, 1770.	1.7	26

#	Article	IF	Citations
55	International Council for Standardization in Haematology (ICSH) recommendations for laboratory measurement of ADAMTS13. International Journal of Laboratory Hematology, 2020, 42, 685-696.	0.7	26
56	Are Myocardial Infarctionâ€“Associated Single-Nucleotide Polymorphisms Associated With Ischemic Stroke?. Stroke, 2012, 43, 980-986.	1.0	25
57	Assessment of current diagnostic practice and efficacy in testing for von Willebrand's disorder: results from the second Australasian multi-laboratory survey. Blood Coagulation and Fibrinolysis, 2000, 11, 729-737.	0.5	23
58	Polymorphisms of the tissue factor pathway inhibitor gene are associated with venous thromboembolism in the antiphospholipid syndrome and carriers of factor V Leiden. Blood Coagulation and Fibrinolysis, 2007, 18, 559-564.	0.5	23
59	Potential supplementary utility of combined PFA-100 and functional von Willebrand factor testing for the laboratory assessment of desmopressin and factor concentrate therapy in von Willebrand disease. Blood Coagulation and Fibrinolysis, 2009, 20, 475-483.	0.5	23
60	Venous thromboembolism in travellers. Blood Coagulation and Fibrinolysis, 2003, 14, 671-675.	0.5	21
61	Restored platelet function after romiplostim treatment in a patient with immune thrombocytopenic purpura. British Journal of Haematology, 2010, 149, 625-628.	1.2	20
62	Upregulation of protein S by progestins. Journal of Thrombosis and Haemostasis, 2007, 5, 2243-2249.	1.9	19
63	A rapid flow cytometric technique for the detection of plateletâ€monocyte complexes, activated platelets and plateletâ€derived microparticles. International Journal of Laboratory Hematology, 2009, 31, 430-439.	0.7	19
64	Circulating MicroRNA as Thrombosis Sentinels: Caveats and Considerations. Seminars in Thrombosis and Hemostasis, 2018, 44, 206-215.	1.5	18
65	How I treat bleeding disorder of unknown cause. Blood, 2021, 138, 1795-1804.	0.6	18
66	Investigation of coagulopathy in three cases of tiger snake (Notechis ater occidentalis) envenomation. Pathology, 2002, 34, 157-161.	0.3	17
67	Pure red cell aplasia of pregnancy: a distinct clinical entity. British Journal of Haematology, 1993, 85, 619-622.	1.2	17
68	Identification of reference miRNAs in plasma useful for the study of oestrogen-responsive miRNAs associated with acquired Protein S deficiency in pregnancy. BMC Research Notes, 2017, 10, 312.	0.6	17
69	The tissue factor pathway in ischemic stroke. Blood Coagulation and Fibrinolysis, 2006, 17, 527-532.	0.5	15
70	Low-molecular-weight Heparin for the treatment of venous thrombosis in patients with adenocarcinoma. , 1998, 59, 260-261.		14
71	Crossâ€reactivity to porcine factor VIII of factor VIII inhibitors in patients with haemophilia in Australia and New Zealand. Australian and New Zealand Journal of Medicine, 1997, 27, 658-664.	0.5	13
72	Undiagnosed Myeloproliferative Disease in Cases of Intra-Abdominal Thrombosis: The Utility of the JAK2 617F Mutation. Clinical Gastroenterology and Hepatology, 2008, 6, 472-475.	2.4	13

#	Article	IF	Citations
73	A novel ABCA1 nonsense mutation, R1270X, in Tangier disease associated with an unrecognised bleeding tendency. Clinica Chimica Acta, 2009, 409, 136-139.	0.5	13
74	Reducing the effect of DOAC interference in laboratory testing for factor VIII and factor IX: A comparative study using DOAC Stop and andexanet alfa to neutralize rivaroxaban effects. Haemophilia, 2020, 26, 354-362.	1.0	13
75	Diagnosis of activated protein C resistance (factor V Leiden). Lancet, The, 1994, 344, 1162.	6.3	12
76	Laboratory testing for activated protein C resistance: rivaroxaban induced interference and a comparative evaluation of andexanet alfa and DOAC Stop to neutralise interference. Clinical Chemistry and Laboratory Medicine, 2020, 58, 1322-1331.	1.4	11
77	Laboratory Diagnosis of von Willebrand Disorder: Use of Multiple Functional Assays Reduces Diagnostic Error Rates. Laboratory Hematology: Official Publication of the International Society for Laboratory Hematology, 2005, 11, 91-97.	1.2	11
78	Low-dose combination chemotherapy for acute myeloid leukemia in elderly patients: A novel approach. , 1997, 55, 115-117.		10
79	Polymorphisms in the tissue factor pathway inhibitor gene are not associated with ischaemic stroke. Blood Coagulation and Fibrinolysis, 2007, 18, 703-708.	0.5	10
80	Low bleeding rates with increase or maintenance of physical activity in patients treated with recombinant factor <scp>VIII</scp> Fc fusion protein (<scp>rFVIIIF</scp>c) in the Aâ€ŁONG and Kids Aâ€‹<scp>LONG</scp> Studies. Haemophilia, 2017, 23, e39-e42.	1.0	10
81	Patient satisfaction after conversion from warfarin to direct oral anticoagulants for patients on extended duration of anticoagulation for venous thromboembolism â€“ The SWAN Study. PLoS ONE, 2020, 15, e0234048.	1.1	10
82	Prognostic utility of ADAMTS13 activity for the atypical hemolytic uremic syndrome (aHUS) and comparison of complement serology between aHUS and thrombotic thrombocytopenic purpura. Blood Research, 2019, 54, 218-228.	0.5	9
83	Type 2B von Willebrand's disease in thirteen individuals from five unrelated Australian families: Phenotype and genotype correlations. , 2000, 63, 197-199.		8
84	Is There Really a Power Shortage in Clinical Trials Testing the â€œHomocysteine Hypothesis?â€• Arteriosclerosis, Thrombosis, and Vascular Biology, 2004, 24, e147.	1.1	8
85	Management of platelet storage pool deficiency during pregnancy. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2003, 43, 171-172.	0.4	7
86	Examining international practices in the management of pregnant women with von Willebrand disease. Journal of Thrombosis and Haemostasis, 2022, 20, 82-91.	1.9	7
87	Hepatitis C genotypes in Australian haemophilia patients. Australian and New Zealand Journal of Medicine, 1996, 26, 789-792.	0.5	6
88	Clinical characteristics and outcomes of thrombotic microangiopathy in Malaysia. Blood Research, 2018, 53, 130.	0.5	6
89	Detection of protein s deficiency: a new functional assay compared to an antigenic technique. Pathology, 2000, 32, 94-97.	0.3	5
90	Pre-operative hemostatic assessment and management. Transfusion and Apheresis Science, 2002, 27, 45-53.	0.5	5

#	Article	IF	Citations
91	Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Patients with Renal Impairment: Ikema Subgroup Analysis. Blood, 2020, 136, 46-47.	0.6	5
92	COLCHICINE THERAPY FOR IDIOPATHIC THROMBOCYTOPENIC PURPURAâ€"AN INEXPENSIVE ALTERNATIVE. Australian and New Zealand Journal of Medicine, 1989, 19, 412-413.	0.5	4
93	Therapeutic Potential of miR-494 in Thrombosis and Other Diseases: A Review. Australian Journal of Chemistry, 2016, 69, 1078.	0.5	4
94	Dimeric FcÎ³R ectodomains detect pathogenic anti-platelet factor 4-heparin antibodies in heparin-induced thromobocytopenia. Journal of Thrombosis and Haemostasis, 2018, 16, 2520-2525.	1.9	4
95	Estradiol-Responsive miR-365a-3p Interacts with Tissue Factor 3â€²UTR to Modulate Tissue Factor-Initiated Thrombin Generation. Thrombosis and Haemostasis, 2021, 121, 1483-1496.	1.8	4
96	CYTOPENIAS INDUCED BY METHOTREXATE IN INFLAMMATORY ARTHRITIS. Australian and New Zealand Journal of Medicine, 1989, 19, 747-747.	0.5	3
97	Avoiding adverse events with dabigatran by careful selection of eligible patients. Medical Journal of Australia, 2012, 196, 431-432.	0.8	3
98	Does activated protein C resistance increase the risk of systemic embolism in non rheumatic atrial fibrillation?. Australian and New Zealand Journal of Medicine, 1996, 26, 243-244.	0.5	2
99	Single or duplicate analysis for automated prothrombin time and activated partial thromboplastin time?. Pathology, 1997, 29, 67-71.	0.3	2
100	Determination of activated protein C resistance in anticoagulated and lupus positive patients. Blood Coagulation and Fibrinolysis, 2000, 11, 439-445.	0.5	2
101	Fc Binding by FcÎ³RIIa Is Essential for Cellular Activation by the Anti-FcÎ³RIIa mAbs 8.26 and 8.2. Frontiers in Immunology, 2021, 12, 666813.	2.2	2
102	Methylene tetrahydrofolate reductase mutation and stroke in a monozygotic twin. Australian and New Zealand Journal of Medicine, 1998, 28, 849-850.	0.5	1
103	Unlocked nucleic acid modified primer-based enzymatic polymerization assay: towards allele-specific genotype detection of human platelet antigens. RSC Advances, 2018, 8, 32770-32774.	1.7	1
104	BEDSIDE BLOOD FILTRATION AND RISK OF THROMBOSIS. British Journal of Haematology, 1990, 75, 297-298.	1.2	0
105	Prothrombin 20210A and familial thrombophilia. Blood Coagulation and Fibrinolysis, 1999, 10, 523-527.	0.5	0
106	Broadsheet number 53: activated protein c resistance: diagnosis and clinical management. Pathology, 1999, 31, 365-371.	0.3	0
107	Coagulopathy from tiger snake envenoming and its treatment: authorsâ€™ reply. Pathology, 2002, 34, 590.	0.3	0
108	ROUTINE PREVENTION OF VENOUS THROMBOEMBOLISM AFTER SURGERY: THE TIME FOR ACTION. ANZ Journal of Surgery, 2007, 77, 408-408.	0.3	0

#	Article	IF	Citations
109	Chronic Lymphocytic Leukaemia Is Associated with a Broad Platelet-Function Defect Which Is Exacerbated By Ibrutinib and Acalabrutinib. Blood, 2018, 132, 3756-3756.	0.6	0